Press Releases May 29, 2026 04:01 PM

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals to Participate in Key June Investor Conferences

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
KNSA

Kiniksa Pharmaceuticals International, plc announced management's participation in fireside chats at the Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference in June 2026. Presentations will be webcast live and available for replay on the company's website, highlighting the company's commitment to engaging with investors and showcasing its biopharmaceutical portfolio focused on cardiovascular and other debilitating diseases.

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
KNSA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kiniksa management will present at two major healthcare investor conferences in June 2026.
  • The presentations will be accessible via live webcast and available for replay, allowing broad investor access.
  • Kiniksa is focused on developing novel therapies for diseases with unmet needs, particularly cardiovascular indications.

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:

  • 2026 Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45 a.m. Eastern Time
  • Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9 at 11:20 a.m. Eastern Time

A live webcast of Kiniksa’s presentations will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the events will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
[email protected]


Risks

  • The announcement is primarily about investor relations events without new clinical or financial data, limiting immediate impact on the stock.
  • Uncertainties remain regarding clinical trial outcomes and regulatory approvals that are critical to Kiniksa's future success.
  • The biopharmaceutical sector faces competitive pressures and scientific challenges that could affect the commercial viability of Kiniksa's pipeline.

More from Press Releases

Amid AI Boom, Verisk Launches New View of U.S. Data Center Exposure, Helping Insurers Assess Growing Concentrations of Risk Sep 3, 2026 Reborn Coffee Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements Sep 3, 2026 HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy Sep 3, 2026 LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Sep 3, 2026 Ming Shing Group Holdings Limited Announces Closing of the Acquisition of Meals Through Seasons Limited and Issuance of Consideration Shares and Unsecured Convertible Promissory Notes Sep 2, 2026